nodes	percent_of_prediction	percent_of_DWPC	metapath
Rimonabant—CYP3A4—Thiotepa—urinary bladder cancer	0.125	0.255	CbGbCtD
Rimonabant—CYP1A2—Fluorouracil—urinary bladder cancer	0.0776	0.158	CbGbCtD
Rimonabant—CYP2C9—Fluorouracil—urinary bladder cancer	0.0699	0.143	CbGbCtD
Rimonabant—CYP1A2—Etoposide—urinary bladder cancer	0.0647	0.132	CbGbCtD
Rimonabant—CYP2C9—Cisplatin—urinary bladder cancer	0.0594	0.121	CbGbCtD
Rimonabant—CYP2D6—Doxorubicin—urinary bladder cancer	0.0364	0.0742	CbGbCtD
Rimonabant—CYP3A4—Etoposide—urinary bladder cancer	0.0339	0.0692	CbGbCtD
Rimonabant—CYP3A4—Doxorubicin—urinary bladder cancer	0.0231	0.0472	CbGbCtD
Rimonabant—CNR1—prostate gland—urinary bladder cancer	0.0137	0.26	CbGeAlD
Rimonabant—CYP1A2—urine—urinary bladder cancer	0.00779	0.148	CbGeAlD
Rimonabant—CYP2C9—urine—urinary bladder cancer	0.00739	0.14	CbGeAlD
Rimonabant—CYP3A4—urine—urinary bladder cancer	0.00564	0.107	CbGeAlD
Rimonabant—CYP2D6—urine—urinary bladder cancer	0.00555	0.105	CbGeAlD
Rimonabant—CNR1—lymph node—urinary bladder cancer	0.00437	0.083	CbGeAlD
Rimonabant—CYP1A2—renal system—urinary bladder cancer	0.00191	0.0362	CbGeAlD
Rimonabant—Dizziness—Mitomycin—urinary bladder cancer	0.00164	0.00549	CcSEcCtD
Rimonabant—Infestation NOS—Fluorouracil—urinary bladder cancer	0.00162	0.00541	CcSEcCtD
Rimonabant—Infestation—Fluorouracil—urinary bladder cancer	0.00162	0.00541	CcSEcCtD
Rimonabant—Angiopathy—Thiotepa—urinary bladder cancer	0.00159	0.00533	CcSEcCtD
Rimonabant—Mediastinal disorder—Thiotepa—urinary bladder cancer	0.00158	0.00529	CcSEcCtD
Rimonabant—Vomiting—Mitomycin—urinary bladder cancer	0.00158	0.00528	CcSEcCtD
Rimonabant—Rash—Mitomycin—urinary bladder cancer	0.00157	0.00523	CcSEcCtD
Rimonabant—Dermatitis—Mitomycin—urinary bladder cancer	0.00156	0.00523	CcSEcCtD
Rimonabant—Headache—Mitomycin—urinary bladder cancer	0.00155	0.0052	CcSEcCtD
Rimonabant—Mental disorder—Thiotepa—urinary bladder cancer	0.00154	0.00515	CcSEcCtD
Rimonabant—Malnutrition—Thiotepa—urinary bladder cancer	0.00153	0.00511	CcSEcCtD
Rimonabant—Sinusitis—Fluorouracil—urinary bladder cancer	0.00152	0.00508	CcSEcCtD
Rimonabant—Tension—Thiotepa—urinary bladder cancer	0.0015	0.00502	CcSEcCtD
Rimonabant—Nervousness—Thiotepa—urinary bladder cancer	0.00149	0.00497	CcSEcCtD
Rimonabant—Nausea—Mitomycin—urinary bladder cancer	0.00147	0.00493	CcSEcCtD
Rimonabant—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.00145	0.00486	CcSEcCtD
Rimonabant—CYP2C9—female reproductive system—urinary bladder cancer	0.00145	0.0275	CbGeAlD
Rimonabant—Hypoaesthesia—Fluorouracil—urinary bladder cancer	0.00145	0.00483	CcSEcCtD
Rimonabant—Hiccups—Epirubicin—urinary bladder cancer	0.00141	0.00471	CcSEcCtD
Rimonabant—Infestation NOS—Etoposide—urinary bladder cancer	0.00141	0.0047	CcSEcCtD
Rimonabant—Infestation—Etoposide—urinary bladder cancer	0.00141	0.0047	CcSEcCtD
Rimonabant—CYP3A4—renal system—urinary bladder cancer	0.00138	0.0262	CbGeAlD
Rimonabant—CYP2D6—renal system—urinary bladder cancer	0.00136	0.0258	CbGeAlD
Rimonabant—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.00135	0.00453	CcSEcCtD
Rimonabant—Angiopathy—Gemcitabine—urinary bladder cancer	0.00134	0.00448	CcSEcCtD
Rimonabant—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.00133	0.00445	CcSEcCtD
Rimonabant—Convulsion—Thiotepa—urinary bladder cancer	0.00133	0.00443	CcSEcCtD
Rimonabant—Hiccups—Doxorubicin—urinary bladder cancer	0.0013	0.00436	CcSEcCtD
Rimonabant—Anxiety—Thiotepa—urinary bladder cancer	0.0013	0.00434	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.00129	0.00432	CcSEcCtD
Rimonabant—Hypoaesthesia—Etoposide—urinary bladder cancer	0.00126	0.0042	CcSEcCtD
Rimonabant—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.00124	0.00415	CcSEcCtD
Rimonabant—Infection—Thiotepa—urinary bladder cancer	0.00124	0.00415	CcSEcCtD
Rimonabant—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00122	0.00409	CcSEcCtD
Rimonabant—Skin disorder—Thiotepa—urinary bladder cancer	0.00121	0.00405	CcSEcCtD
Rimonabant—Malnutrition—Cisplatin—urinary bladder cancer	0.0012	0.00401	CcSEcCtD
Rimonabant—Anorexia—Thiotepa—urinary bladder cancer	0.00119	0.00398	CcSEcCtD
Rimonabant—Muscle spasms—Cisplatin—urinary bladder cancer	0.00115	0.00385	CcSEcCtD
Rimonabant—Angiopathy—Etoposide—urinary bladder cancer	0.00115	0.00383	CcSEcCtD
Rimonabant—Mediastinal disorder—Etoposide—urinary bladder cancer	0.00114	0.0038	CcSEcCtD
Rimonabant—Tremor—Cisplatin—urinary bladder cancer	0.00112	0.00376	CcSEcCtD
Rimonabant—Paraesthesia—Thiotepa—urinary bladder cancer	0.00112	0.00375	CcSEcCtD
Rimonabant—Lethargy—Methotrexate—urinary bladder cancer	0.00112	0.00373	CcSEcCtD
Rimonabant—CYP3A4—female reproductive system—urinary bladder cancer	0.0011	0.021	CbGeAlD
Rimonabant—Convulsion—Fluorouracil—urinary bladder cancer	0.0011	0.00366	CcSEcCtD
Rimonabant—Hot flush—Epirubicin—urinary bladder cancer	0.00109	0.00365	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00109	0.00364	CcSEcCtD
Rimonabant—CYP2D6—female reproductive system—urinary bladder cancer	0.00109	0.0206	CbGeAlD
Rimonabant—Decreased appetite—Thiotepa—urinary bladder cancer	0.00109	0.00363	CcSEcCtD
Rimonabant—Menopausal symptoms—Epirubicin—urinary bladder cancer	0.00108	0.00362	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00108	0.0036	CcSEcCtD
Rimonabant—Fatigue—Thiotepa—urinary bladder cancer	0.00108	0.0036	CcSEcCtD
Rimonabant—Muscle spasms—Etoposide—urinary bladder cancer	0.00106	0.00353	CcSEcCtD
Rimonabant—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.00105	0.0035	CcSEcCtD
Rimonabant—Lethargy—Epirubicin—urinary bladder cancer	0.00104	0.00349	CcSEcCtD
Rimonabant—Infection—Gemcitabine—urinary bladder cancer	0.00104	0.00349	CcSEcCtD
Rimonabant—Irritability—Methotrexate—urinary bladder cancer	0.00104	0.00349	CcSEcCtD
Rimonabant—Convulsion—Cisplatin—urinary bladder cancer	0.00104	0.00347	CcSEcCtD
Rimonabant—Mood swings—Methotrexate—urinary bladder cancer	0.00104	0.00346	CcSEcCtD
Rimonabant—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00103	0.00344	CcSEcCtD
Rimonabant—Infection—Fluorouracil—urinary bladder cancer	0.00103	0.00343	CcSEcCtD
Rimonabant—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00102	0.00341	CcSEcCtD
Rimonabant—Skin disorder—Gemcitabine—urinary bladder cancer	0.00102	0.00341	CcSEcCtD
Rimonabant—Anxiety—Cisplatin—urinary bladder cancer	0.00102	0.0034	CcSEcCtD
Rimonabant—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.00102	0.00339	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00101	0.00339	CcSEcCtD
Rimonabant—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00101	0.00338	CcSEcCtD
Rimonabant—Hot flush—Doxorubicin—urinary bladder cancer	0.00101	0.00338	CcSEcCtD
Rimonabant—Menopausal symptoms—Doxorubicin—urinary bladder cancer	0.001	0.00335	CcSEcCtD
Rimonabant—Anorexia—Gemcitabine—urinary bladder cancer	0.001	0.00335	CcSEcCtD
Rimonabant—Abdominal pain—Thiotepa—urinary bladder cancer	0.000987	0.0033	CcSEcCtD
Rimonabant—Anorexia—Fluorouracil—urinary bladder cancer	0.000984	0.00329	CcSEcCtD
Rimonabant—Infection—Cisplatin—urinary bladder cancer	0.000972	0.00325	CcSEcCtD
Rimonabant—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.00097	0.00324	CcSEcCtD
Rimonabant—Mood swings—Epirubicin—urinary bladder cancer	0.000969	0.00324	CcSEcCtD
Rimonabant—Lethargy—Doxorubicin—urinary bladder cancer	0.000966	0.00323	CcSEcCtD
Rimonabant—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00096	0.00321	CcSEcCtD
Rimonabant—Convulsion—Etoposide—urinary bladder cancer	0.000952	0.00318	CcSEcCtD
Rimonabant—Skin disorder—Cisplatin—urinary bladder cancer	0.000951	0.00318	CcSEcCtD
Rimonabant—Insomnia—Gemcitabine—urinary bladder cancer	0.00095	0.00318	CcSEcCtD
Rimonabant—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000946	0.00316	CcSEcCtD
Rimonabant—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000943	0.00315	CcSEcCtD
Rimonabant—Insomnia—Fluorouracil—urinary bladder cancer	0.000934	0.00312	CcSEcCtD
Rimonabant—Anorexia—Cisplatin—urinary bladder cancer	0.000933	0.00312	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000929	0.00311	CcSEcCtD
Rimonabant—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000927	0.0031	CcSEcCtD
Rimonabant—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000913	0.00305	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000907	0.00303	CcSEcCtD
Rimonabant—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000905	0.00303	CcSEcCtD
Rimonabant—Fatigue—Gemcitabine—urinary bladder cancer	0.000905	0.00303	CcSEcCtD
Rimonabant—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000898	0.003	CcSEcCtD
Rimonabant—Mood swings—Doxorubicin—urinary bladder cancer	0.000896	0.003	CcSEcCtD
Rimonabant—Asthenia—Thiotepa—urinary bladder cancer	0.000896	0.00299	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000891	0.00298	CcSEcCtD
Rimonabant—Infection—Etoposide—urinary bladder cancer	0.000891	0.00298	CcSEcCtD
Rimonabant—Influenza—Epirubicin—urinary bladder cancer	0.000884	0.00295	CcSEcCtD
Rimonabant—Pruritus—Thiotepa—urinary bladder cancer	0.000883	0.00295	CcSEcCtD
Rimonabant—Paraesthesia—Cisplatin—urinary bladder cancer	0.000879	0.00294	CcSEcCtD
Rimonabant—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000878	0.00293	CcSEcCtD
Rimonabant—Skin disorder—Etoposide—urinary bladder cancer	0.000871	0.00291	CcSEcCtD
Rimonabant—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000867	0.0029	CcSEcCtD
Rimonabant—Anorexia—Etoposide—urinary bladder cancer	0.000855	0.00286	CcSEcCtD
Rimonabant—Diarrhoea—Thiotepa—urinary bladder cancer	0.000854	0.00286	CcSEcCtD
Rimonabant—Decreased appetite—Cisplatin—urinary bladder cancer	0.000851	0.00284	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000845	0.00282	CcSEcCtD
Rimonabant—Infestation NOS—Methotrexate—urinary bladder cancer	0.000842	0.00282	CcSEcCtD
Rimonabant—Infestation—Methotrexate—urinary bladder cancer	0.000842	0.00282	CcSEcCtD
Rimonabant—Depression—Methotrexate—urinary bladder cancer	0.00084	0.00281	CcSEcCtD
Rimonabant—Dizziness—Thiotepa—urinary bladder cancer	0.000825	0.00276	CcSEcCtD
Rimonabant—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000821	0.00275	CcSEcCtD
Rimonabant—Influenza—Doxorubicin—urinary bladder cancer	0.000818	0.00273	CcSEcCtD
Rimonabant—Paraesthesia—Etoposide—urinary bladder cancer	0.000805	0.00269	CcSEcCtD
Rimonabant—Vomiting—Thiotepa—urinary bladder cancer	0.000794	0.00265	CcSEcCtD
Rimonabant—Infestation NOS—Epirubicin—urinary bladder cancer	0.000788	0.00263	CcSEcCtD
Rimonabant—Infestation—Epirubicin—urinary bladder cancer	0.000788	0.00263	CcSEcCtD
Rimonabant—Rash—Thiotepa—urinary bladder cancer	0.000787	0.00263	CcSEcCtD
Rimonabant—Dermatitis—Thiotepa—urinary bladder cancer	0.000786	0.00263	CcSEcCtD
Rimonabant—Headache—Thiotepa—urinary bladder cancer	0.000782	0.00261	CcSEcCtD
Rimonabant—Decreased appetite—Etoposide—urinary bladder cancer	0.000779	0.00261	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000774	0.00259	CcSEcCtD
Rimonabant—Fatigue—Etoposide—urinary bladder cancer	0.000773	0.00258	CcSEcCtD
Rimonabant—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.00076	0.00254	CcSEcCtD
Rimonabant—Asthenia—Gemcitabine—urinary bladder cancer	0.000753	0.00252	CcSEcCtD
Rimonabant—Pruritus—Gemcitabine—urinary bladder cancer	0.000743	0.00248	CcSEcCtD
Rimonabant—Nausea—Thiotepa—urinary bladder cancer	0.000741	0.00248	CcSEcCtD
Rimonabant—Sinusitis—Epirubicin—urinary bladder cancer	0.000739	0.00247	CcSEcCtD
Rimonabant—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000733	0.00245	CcSEcCtD
Rimonabant—Pruritus—Fluorouracil—urinary bladder cancer	0.00073	0.00244	CcSEcCtD
Rimonabant—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000729	0.00244	CcSEcCtD
Rimonabant—Infestation—Doxorubicin—urinary bladder cancer	0.000729	0.00244	CcSEcCtD
Rimonabant—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000718	0.0024	CcSEcCtD
Rimonabant—Abdominal pain—Etoposide—urinary bladder cancer	0.000709	0.00237	CcSEcCtD
Rimonabant—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000706	0.00236	CcSEcCtD
Rimonabant—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000704	0.00235	CcSEcCtD
Rimonabant—Asthenia—Cisplatin—urinary bladder cancer	0.000702	0.00235	CcSEcCtD
Rimonabant—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000695	0.00232	CcSEcCtD
Rimonabant—Angiopathy—Methotrexate—urinary bladder cancer	0.000686	0.00229	CcSEcCtD
Rimonabant—Sinusitis—Doxorubicin—urinary bladder cancer	0.000684	0.00229	CcSEcCtD
Rimonabant—Dizziness—Fluorouracil—urinary bladder cancer	0.000683	0.00228	CcSEcCtD
Rimonabant—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000681	0.00228	CcSEcCtD
Rimonabant—Diarrhoea—Cisplatin—urinary bladder cancer	0.00067	0.00224	CcSEcCtD
Rimonabant—Vomiting—Gemcitabine—urinary bladder cancer	0.000668	0.00223	CcSEcCtD
Rimonabant—Mental disorder—Methotrexate—urinary bladder cancer	0.000662	0.00221	CcSEcCtD
Rimonabant—Rash—Gemcitabine—urinary bladder cancer	0.000662	0.00221	CcSEcCtD
Rimonabant—Dermatitis—Gemcitabine—urinary bladder cancer	0.000661	0.00221	CcSEcCtD
Rimonabant—Malnutrition—Methotrexate—urinary bladder cancer	0.000658	0.0022	CcSEcCtD
Rimonabant—Headache—Gemcitabine—urinary bladder cancer	0.000658	0.0022	CcSEcCtD
Rimonabant—Vomiting—Fluorouracil—urinary bladder cancer	0.000656	0.00219	CcSEcCtD
Rimonabant—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000651	0.00218	CcSEcCtD
Rimonabant—Rash—Fluorouracil—urinary bladder cancer	0.000651	0.00218	CcSEcCtD
Rimonabant—Dermatitis—Fluorouracil—urinary bladder cancer	0.00065	0.00217	CcSEcCtD
Rimonabant—Headache—Fluorouracil—urinary bladder cancer	0.000647	0.00216	CcSEcCtD
Rimonabant—Asthenia—Etoposide—urinary bladder cancer	0.000643	0.00215	CcSEcCtD
Rimonabant—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000643	0.00215	CcSEcCtD
Rimonabant—Angiopathy—Epirubicin—urinary bladder cancer	0.000642	0.00215	CcSEcCtD
Rimonabant—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000638	0.00213	CcSEcCtD
Rimonabant—Pruritus—Etoposide—urinary bladder cancer	0.000634	0.00212	CcSEcCtD
Rimonabant—Nausea—Gemcitabine—urinary bladder cancer	0.000624	0.00209	CcSEcCtD
Rimonabant—Vomiting—Cisplatin—urinary bladder cancer	0.000622	0.00208	CcSEcCtD
Rimonabant—Mental disorder—Epirubicin—urinary bladder cancer	0.00062	0.00207	CcSEcCtD
Rimonabant—Rash—Cisplatin—urinary bladder cancer	0.000617	0.00206	CcSEcCtD
Rimonabant—Dermatitis—Cisplatin—urinary bladder cancer	0.000617	0.00206	CcSEcCtD
Rimonabant—Malnutrition—Epirubicin—urinary bladder cancer	0.000616	0.00206	CcSEcCtD
Rimonabant—Diarrhoea—Etoposide—urinary bladder cancer	0.000614	0.00205	CcSEcCtD
Rimonabant—Nausea—Fluorouracil—urinary bladder cancer	0.000613	0.00205	CcSEcCtD
Rimonabant—Tension—Epirubicin—urinary bladder cancer	0.000604	0.00202	CcSEcCtD
Rimonabant—Nervousness—Epirubicin—urinary bladder cancer	0.000598	0.002	CcSEcCtD
Rimonabant—Angiopathy—Doxorubicin—urinary bladder cancer	0.000594	0.00199	CcSEcCtD
Rimonabant—Dizziness—Etoposide—urinary bladder cancer	0.000593	0.00198	CcSEcCtD
Rimonabant—Muscle spasms—Epirubicin—urinary bladder cancer	0.000592	0.00198	CcSEcCtD
Rimonabant—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.00059	0.00197	CcSEcCtD
Rimonabant—Nausea—Cisplatin—urinary bladder cancer	0.000581	0.00194	CcSEcCtD
Rimonabant—Mental disorder—Doxorubicin—urinary bladder cancer	0.000573	0.00192	CcSEcCtD
Rimonabant—Convulsion—Methotrexate—urinary bladder cancer	0.00057	0.00191	CcSEcCtD
Rimonabant—Vomiting—Etoposide—urinary bladder cancer	0.00057	0.00191	CcSEcCtD
Rimonabant—Malnutrition—Doxorubicin—urinary bladder cancer	0.00057	0.0019	CcSEcCtD
Rimonabant—Rash—Etoposide—urinary bladder cancer	0.000565	0.00189	CcSEcCtD
Rimonabant—Dermatitis—Etoposide—urinary bladder cancer	0.000565	0.00189	CcSEcCtD
Rimonabant—Headache—Etoposide—urinary bladder cancer	0.000562	0.00188	CcSEcCtD
Rimonabant—Tension—Doxorubicin—urinary bladder cancer	0.000559	0.00187	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000556	0.00186	CcSEcCtD
Rimonabant—Nervousness—Doxorubicin—urinary bladder cancer	0.000553	0.00185	CcSEcCtD
Rimonabant—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000548	0.00183	CcSEcCtD
Rimonabant—Convulsion—Epirubicin—urinary bladder cancer	0.000534	0.00178	CcSEcCtD
Rimonabant—Infection—Methotrexate—urinary bladder cancer	0.000534	0.00178	CcSEcCtD
Rimonabant—Nausea—Etoposide—urinary bladder cancer	0.000533	0.00178	CcSEcCtD
Rimonabant—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000527	0.00176	CcSEcCtD
Rimonabant—Anxiety—Epirubicin—urinary bladder cancer	0.000523	0.00175	CcSEcCtD
Rimonabant—Skin disorder—Methotrexate—urinary bladder cancer	0.000522	0.00174	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000521	0.00174	CcSEcCtD
Rimonabant—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000519	0.00174	CcSEcCtD
Rimonabant—Dry mouth—Epirubicin—urinary bladder cancer	0.000513	0.00171	CcSEcCtD
Rimonabant—Anorexia—Methotrexate—urinary bladder cancer	0.000512	0.00171	CcSEcCtD
Rimonabant—Infection—Epirubicin—urinary bladder cancer	0.000499	0.00167	CcSEcCtD
Rimonabant—Convulsion—Doxorubicin—urinary bladder cancer	0.000494	0.00165	CcSEcCtD
Rimonabant—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000493	0.00165	CcSEcCtD
Rimonabant—Skin disorder—Epirubicin—urinary bladder cancer	0.000488	0.00163	CcSEcCtD
Rimonabant—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000486	0.00162	CcSEcCtD
Rimonabant—Insomnia—Methotrexate—urinary bladder cancer	0.000486	0.00162	CcSEcCtD
Rimonabant—Anxiety—Doxorubicin—urinary bladder cancer	0.000483	0.00162	CcSEcCtD
Rimonabant—Paraesthesia—Methotrexate—urinary bladder cancer	0.000482	0.00161	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000482	0.00161	CcSEcCtD
Rimonabant—Anorexia—Epirubicin—urinary bladder cancer	0.000479	0.0016	CcSEcCtD
Rimonabant—Dry mouth—Doxorubicin—urinary bladder cancer	0.000474	0.00159	CcSEcCtD
Rimonabant—Decreased appetite—Methotrexate—urinary bladder cancer	0.000467	0.00156	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000464	0.00155	CcSEcCtD
Rimonabant—Fatigue—Methotrexate—urinary bladder cancer	0.000463	0.00155	CcSEcCtD
Rimonabant—Infection—Doxorubicin—urinary bladder cancer	0.000462	0.00154	CcSEcCtD
Rimonabant—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000456	0.00152	CcSEcCtD
Rimonabant—Insomnia—Epirubicin—urinary bladder cancer	0.000455	0.00152	CcSEcCtD
Rimonabant—Skin disorder—Doxorubicin—urinary bladder cancer	0.000452	0.00151	CcSEcCtD
Rimonabant—Paraesthesia—Epirubicin—urinary bladder cancer	0.000451	0.00151	CcSEcCtD
Rimonabant—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.00045	0.0015	CcSEcCtD
Rimonabant—Anorexia—Doxorubicin—urinary bladder cancer	0.000443	0.00148	CcSEcCtD
Rimonabant—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000439	0.00147	CcSEcCtD
Rimonabant—Decreased appetite—Epirubicin—urinary bladder cancer	0.000437	0.00146	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000434	0.00145	CcSEcCtD
Rimonabant—Fatigue—Epirubicin—urinary bladder cancer	0.000433	0.00145	CcSEcCtD
Rimonabant—Abdominal pain—Methotrexate—urinary bladder cancer	0.000425	0.00142	CcSEcCtD
Rimonabant—Insomnia—Doxorubicin—urinary bladder cancer	0.000421	0.00141	CcSEcCtD
Rimonabant—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000419	0.00265	CbGpPWpGaD
Rimonabant—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000418	0.0014	CcSEcCtD
Rimonabant—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000411	0.00137	CcSEcCtD
Rimonabant—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000404	0.00135	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000402	0.00134	CcSEcCtD
Rimonabant—Fatigue—Doxorubicin—urinary bladder cancer	0.000401	0.00134	CcSEcCtD
Rimonabant—CNR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000399	0.00252	CbGpPWpGaD
Rimonabant—Abdominal pain—Epirubicin—urinary bladder cancer	0.000397	0.00133	CcSEcCtD
Rimonabant—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000389	0.00246	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000387	0.00245	CbGpPWpGaD
Rimonabant—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000386	0.00244	CbGpPWpGaD
Rimonabant—Asthenia—Methotrexate—urinary bladder cancer	0.000385	0.00129	CcSEcCtD
Rimonabant—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000384	0.00243	CbGpPWpGaD
Rimonabant—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000382	0.00242	CbGpPWpGaD
Rimonabant—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00038	0.0024	CbGpPWpGaD
Rimonabant—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.00038	0.00127	CcSEcCtD
Rimonabant—Pruritus—Methotrexate—urinary bladder cancer	0.00038	0.00127	CcSEcCtD
Rimonabant—CNR1—Signaling Pathways—GLI1—urinary bladder cancer	0.000377	0.00239	CbGpPWpGaD
Rimonabant—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000377	0.00238	CbGpPWpGaD
Rimonabant—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000368	0.00123	CcSEcCtD
Rimonabant—Diarrhoea—Methotrexate—urinary bladder cancer	0.000367	0.00123	CcSEcCtD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000367	0.00232	CbGpPWpGaD
Rimonabant—Asthenia—Epirubicin—urinary bladder cancer	0.000361	0.00121	CcSEcCtD
Rimonabant—Pruritus—Epirubicin—urinary bladder cancer	0.000356	0.00119	CcSEcCtD
Rimonabant—Dizziness—Methotrexate—urinary bladder cancer	0.000355	0.00119	CcSEcCtD
Rimonabant—Diarrhoea—Epirubicin—urinary bladder cancer	0.000344	0.00115	CcSEcCtD
Rimonabant—Vomiting—Methotrexate—urinary bladder cancer	0.000341	0.00114	CcSEcCtD
Rimonabant—Rash—Methotrexate—urinary bladder cancer	0.000339	0.00113	CcSEcCtD
Rimonabant—Dermatitis—Methotrexate—urinary bladder cancer	0.000338	0.00113	CcSEcCtD
Rimonabant—Headache—Methotrexate—urinary bladder cancer	0.000336	0.00112	CcSEcCtD
Rimonabant—Asthenia—Doxorubicin—urinary bladder cancer	0.000334	0.00112	CcSEcCtD
Rimonabant—Dizziness—Epirubicin—urinary bladder cancer	0.000332	0.00111	CcSEcCtD
Rimonabant—CNR2—Signaling Pathways—RBX1—urinary bladder cancer	0.00033	0.00208	CbGpPWpGaD
Rimonabant—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	0.00033	0.00208	CbGpPWpGaD
Rimonabant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000329	0.00208	CbGpPWpGaD
Rimonabant—Pruritus—Doxorubicin—urinary bladder cancer	0.000329	0.0011	CcSEcCtD
Rimonabant—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000325	0.00205	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000321	0.00203	CbGpPWpGaD
Rimonabant—Vomiting—Epirubicin—urinary bladder cancer	0.00032	0.00107	CcSEcCtD
Rimonabant—Nausea—Methotrexate—urinary bladder cancer	0.000319	0.00107	CcSEcCtD
Rimonabant—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000318	0.00106	CcSEcCtD
Rimonabant—Rash—Epirubicin—urinary bladder cancer	0.000317	0.00106	CcSEcCtD
Rimonabant—Dermatitis—Epirubicin—urinary bladder cancer	0.000317	0.00106	CcSEcCtD
Rimonabant—Headache—Epirubicin—urinary bladder cancer	0.000315	0.00105	CcSEcCtD
Rimonabant—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000311	0.00197	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—TSC1—urinary bladder cancer	0.00031	0.00196	CbGpPWpGaD
Rimonabant—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000308	0.00195	CbGpPWpGaD
Rimonabant—Dizziness—Doxorubicin—urinary bladder cancer	0.000308	0.00103	CcSEcCtD
Rimonabant—CNR1—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000304	0.00192	CbGpPWpGaD
Rimonabant—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000303	0.00191	CbGpPWpGaD
Rimonabant—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000302	0.00191	CbGpPWpGaD
Rimonabant—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000299	0.00189	CbGpPWpGaD
Rimonabant—Nausea—Epirubicin—urinary bladder cancer	0.000299	0.000998	CcSEcCtD
Rimonabant—Vomiting—Doxorubicin—urinary bladder cancer	0.000296	0.000989	CcSEcCtD
Rimonabant—CNR2—Signaling Pathways—JAG1—urinary bladder cancer	0.000295	0.00186	CbGpPWpGaD
Rimonabant—Rash—Doxorubicin—urinary bladder cancer	0.000293	0.00098	CcSEcCtD
Rimonabant—Dermatitis—Doxorubicin—urinary bladder cancer	0.000293	0.000979	CcSEcCtD
Rimonabant—Headache—Doxorubicin—urinary bladder cancer	0.000291	0.000974	CcSEcCtD
Rimonabant—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000288	0.00182	CbGpPWpGaD
Rimonabant—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000278	0.00176	CbGpPWpGaD
Rimonabant—Nausea—Doxorubicin—urinary bladder cancer	0.000276	0.000923	CcSEcCtD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000264	0.00167	CbGpPWpGaD
Rimonabant—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.000263	0.00167	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—RBX1—urinary bladder cancer	0.000259	0.00163	CbGpPWpGaD
Rimonabant—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000255	0.00162	CbGpPWpGaD
Rimonabant—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000254	0.00161	CbGpPWpGaD
Rimonabant—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000251	0.00159	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000249	0.00158	CbGpPWpGaD
Rimonabant—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000247	0.00156	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000244	0.00154	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—TSC1—urinary bladder cancer	0.000243	0.00154	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—S100B—urinary bladder cancer	0.000239	0.00151	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—JAG1—urinary bladder cancer	0.000231	0.00146	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.00023	0.00146	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—RHOA—urinary bladder cancer	0.000226	0.00143	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000223	0.00141	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000219	0.00139	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000219	0.00139	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000219	0.00138	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—NCOR1—urinary bladder cancer	0.000215	0.00136	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000213	0.00135	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000213	0.00135	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—IL2—urinary bladder cancer	0.000209	0.00132	CbGpPWpGaD
Rimonabant—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000209	0.00132	CbGpPWpGaD
Rimonabant—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000207	0.00131	CbGpPWpGaD
Rimonabant—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000206	0.0013	CbGpPWpGaD
Rimonabant—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000204	0.00129	CbGpPWpGaD
Rimonabant—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000203	0.00129	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000199	0.00126	CbGpPWpGaD
Rimonabant—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000197	0.00125	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000196	0.00124	CbGpPWpGaD
Rimonabant—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.000192	0.00121	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000191	0.00121	CbGpPWpGaD
Rimonabant—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.00019	0.0012	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.00019	0.0012	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—IL2—urinary bladder cancer	0.00019	0.0012	CbGpPWpGaD
Rimonabant—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000189	0.0012	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—TERT—urinary bladder cancer	0.000189	0.0012	CbGpPWpGaD
Rimonabant—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000188	0.00119	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—S100B—urinary bladder cancer	0.000187	0.00118	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000187	0.00118	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000187	0.00118	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000178	0.00112	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000178	0.00112	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—RHOA—urinary bladder cancer	0.000178	0.00112	CbGpPWpGaD
Rimonabant—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	0.000177	0.00112	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000176	0.00112	CbGpPWpGaD
Rimonabant—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000175	0.0011	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—FGFR3—urinary bladder cancer	0.000174	0.0011	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000172	0.00109	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—ESR1—urinary bladder cancer	0.000169	0.00107	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—NCOR1—urinary bladder cancer	0.000169	0.00107	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—IL2—urinary bladder cancer	0.000164	0.00104	CbGpPWpGaD
Rimonabant—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	0.000163	0.00103	CbGpPWpGaD
Rimonabant—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000161	0.00101	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000156	0.000986	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.00015	0.000948	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—IL2—urinary bladder cancer	0.000149	0.000942	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—TERT—urinary bladder cancer	0.000149	0.000939	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CREBBP—urinary bladder cancer	0.000148	0.000935	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—IGF1—urinary bladder cancer	0.000146	0.000923	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—EGFR—urinary bladder cancer	0.000145	0.000919	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—KRAS—urinary bladder cancer	0.000137	0.000868	CbGpPWpGaD
Rimonabant—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.000137	0.000864	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—FGFR3—urinary bladder cancer	0.000136	0.000862	CbGpPWpGaD
Rimonabant—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000135	0.000852	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—RHOA—urinary bladder cancer	0.000134	0.000846	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—ESR1—urinary bladder cancer	0.000132	0.000837	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	0.000128	0.00081	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	0.000127	0.000803	CbGpPWpGaD
Rimonabant—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000126	0.000794	CbGpPWpGaD
Rimonabant—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000124	0.000783	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—ERBB2—urinary bladder cancer	0.000124	0.000783	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	0.000121	0.000767	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—NAT1—urinary bladder cancer	0.000121	0.000767	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	0.00012	0.000761	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—NAT1—urinary bladder cancer	0.00012	0.000761	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000118	0.000748	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CXCL8—urinary bladder cancer	0.000117	0.000742	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—HRAS—urinary bladder cancer	0.000117	0.000738	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CREBBP—urinary bladder cancer	0.000116	0.000733	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—IGF1—urinary bladder cancer	0.000115	0.000724	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—EGFR—urinary bladder cancer	0.000114	0.000721	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—IL2—urinary bladder cancer	0.000112	0.000709	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	0.000111	0.000702	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	0.00011	0.000696	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CCND1—urinary bladder cancer	0.000109	0.000692	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	0.000108	0.000686	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—KRAS—urinary bladder cancer	0.000108	0.000681	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—MMP9—urinary bladder cancer	0.000106	0.000671	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CDKN1A—urinary bladder cancer	0.000106	0.000669	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—PTEN—urinary bladder cancer	0.000106	0.000668	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—RHOA—urinary bladder cancer	0.000105	0.000664	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	0.000103	0.00065	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—NAT1—urinary bladder cancer	0.000103	0.00065	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000101	0.000639	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—EP300—urinary bladder cancer	0.000101	0.000637	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	0.0001	0.000632	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	9.91e-05	0.000627	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—SRC—urinary bladder cancer	9.79e-05	0.000619	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—ERBB2—urinary bladder cancer	9.72e-05	0.000614	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	9.44e-05	0.000597	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	9.41e-05	0.000595	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	9.36e-05	0.000592	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CXCL8—urinary bladder cancer	9.21e-05	0.000583	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	9.2e-05	0.000582	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—HRAS—urinary bladder cancer	9.16e-05	0.000579	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	9.12e-05	0.000577	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—IL2—urinary bladder cancer	8.81e-05	0.000557	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—MYC—urinary bladder cancer	8.78e-05	0.000555	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CCND1—urinary bladder cancer	8.58e-05	0.000543	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—EGFR—urinary bladder cancer	8.58e-05	0.000543	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	8.47e-05	0.000535	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	8.37e-05	0.000529	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—MMP9—urinary bladder cancer	8.33e-05	0.000527	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CDKN1A—urinary bladder cancer	8.3e-05	0.000525	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—PTEN—urinary bladder cancer	8.29e-05	0.000524	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—KRAS—urinary bladder cancer	8.11e-05	0.000513	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	8e-05	0.000506	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—NAT1—urinary bladder cancer	7.94e-05	0.000502	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	7.94e-05	0.000502	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—EP300—urinary bladder cancer	7.9e-05	0.0005	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	7.79e-05	0.000493	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—SRC—urinary bladder cancer	7.68e-05	0.000486	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—TYMP—urinary bladder cancer	7.36e-05	0.000465	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	7.31e-05	0.000462	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—TYMP—urinary bladder cancer	7.29e-05	0.000461	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	7.26e-05	0.000459	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—TP53—urinary bladder cancer	7.21e-05	0.000456	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7e-05	0.000443	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—HRAS—urinary bladder cancer	6.89e-05	0.000436	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—MYC—urinary bladder cancer	6.89e-05	0.000435	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—EGFR—urinary bladder cancer	6.74e-05	0.000426	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—NAT2—urinary bladder cancer	6.65e-05	0.000421	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—NAT2—urinary bladder cancer	6.59e-05	0.000417	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	6.54e-05	0.000413	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—KRAS—urinary bladder cancer	6.36e-05	0.000402	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.25e-05	0.000395	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—TYMP—urinary bladder cancer	6.23e-05	0.000394	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	6.17e-05	0.00039	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	6.02e-05	0.00038	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.98e-05	0.000378	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—RRM2—urinary bladder cancer	5.74e-05	0.000363	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—RRM2—urinary bladder cancer	5.69e-05	0.00036	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—TP53—urinary bladder cancer	5.65e-05	0.000357	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—NAT2—urinary bladder cancer	5.64e-05	0.000356	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—HRAS—urinary bladder cancer	5.41e-05	0.000342	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—ENO2—urinary bladder cancer	5.32e-05	0.000336	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	5.32e-05	0.000336	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	5.27e-05	0.000333	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—ENO2—urinary bladder cancer	5.27e-05	0.000333	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.24e-05	0.000331	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	5.16e-05	0.000326	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	5.11e-05	0.000323	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.03e-05	0.000318	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—RRM2—urinary bladder cancer	4.86e-05	0.000308	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—TYMP—urinary bladder cancer	4.81e-05	0.000304	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	4.5e-05	0.000285	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—ENO2—urinary bladder cancer	4.5e-05	0.000285	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.48e-05	0.000283	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	4.37e-05	0.000276	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—NAT2—urinary bladder cancer	4.35e-05	0.000275	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.3e-05	0.000272	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—NQO1—urinary bladder cancer	4.29e-05	0.000271	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—NQO1—urinary bladder cancer	4.25e-05	0.000269	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.12e-05	0.000261	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.75e-05	0.000237	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—NQO1—urinary bladder cancer	3.63e-05	0.00023	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.6e-05	0.000227	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	3.58e-05	0.000226	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	3.54e-05	0.000224	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.52e-05	0.000223	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.48e-05	0.00022	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.48e-05	0.00022	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.43e-05	0.000217	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.37e-05	0.000213	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—TYMS—urinary bladder cancer	3.32e-05	0.00021	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—TYMS—urinary bladder cancer	3.29e-05	0.000208	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	3.29e-05	0.000208	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	3.29e-05	0.000208	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	3.26e-05	0.000206	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	3.26e-05	0.000206	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—GPX1—urinary bladder cancer	3.15e-05	0.000199	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—GPX1—urinary bladder cancer	3.12e-05	0.000197	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	3.09e-05	0.000195	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.07e-05	0.000194	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	3.06e-05	0.000194	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	3.03e-05	0.000191	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.93e-05	0.000185	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2.9e-05	0.000184	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.88e-05	0.000182	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—TYMS—urinary bladder cancer	2.82e-05	0.000178	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.8e-05	0.000177	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	2.78e-05	0.000176	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	2.78e-05	0.000176	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—GPX1—urinary bladder cancer	2.67e-05	0.000168	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	2.62e-05	0.000165	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	2.46e-05	0.000155	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PPARG—urinary bladder cancer	2.35e-05	0.000149	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.34e-05	0.000148	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2.33e-05	0.000148	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	2.26e-05	0.000143	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	2.24e-05	0.000142	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.17e-05	0.000137	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.15e-05	0.000136	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.15e-05	0.000136	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.06e-05	0.00013	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.02e-05	0.000128	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.99e-05	0.000126	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.92e-05	0.000121	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.9e-05	0.00012	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.85e-05	0.000117	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.84e-05	0.000116	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.62e-05	0.000102	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.6e-05	0.000101	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.57e-05	9.92e-05	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.54e-05	9.74e-05	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.54e-05	9.73e-05	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.53e-05	9.65e-05	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.48e-05	9.35e-05	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.37e-05	8.65e-05	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.3e-05	8.25e-05	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.21e-05	7.66e-05	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.06e-05	6.68e-05	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.01e-05	6.37e-05	CbGpPWpGaD
